REFERENCES

• MauskopfJ.MuroffM.GibsonPJ.GraingerDL.Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia.Schizophr Bull.20022861963512795495
   PubMed Web of Science ®Google Scholar
• LeuchtS.WahlbeckK.HamannJ.KisslingW.New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.Lancet.20033611581158912747876
   PubMed Web of Science ®Google Scholar
• PeuskensJ.The evolving definition of treatment resistance.J Clin Psychiatry.199960(suppl 12)4810372602
   PubMed Web of Science ®Google Scholar
• GeddesJ.FreemantleN.HarrisonP.BebbingtonP.Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis.BMJ.20003211371137611099280
   PubMed Web of Science ®Google Scholar
• LeuchtS.Pitschel-WalzG.AbrahamD.KisslingW.Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.Schizophr Res.19993551689988841
   PubMed Web of Science ®Google Scholar
• DavisJM.SchafferCB.KillianGA.KinardC.ChanC.Important issues in the drug treatment of schizophrenia.Schizophr Bull.1980670876102795
   PubMed Web of Science ®Google Scholar
• CrowTJ.MacMillanJF.JohnsonAL.JohnstoneEC.A randomised controlled trial of prophylactic neuroleptic treatment.Br J Psychiatry.19861481201272870753
   PubMed Web of Science ®Google Scholar
• LiebermanJ.JodyD.GeislerS.et al.Time course and biologic correlates of treatment response in first-episode schizophrenia.Arch Gen Psychiatry.1993503693768098203
   PubMed Web of Science ®Google Scholar
• MeltzerHY.Defining treatment refractoriness in schizophrenia.Schizophr Bull.1990165635652077634
   PubMed Web of Science ®Google Scholar
• EssockSM.HargreavesWA.CovellNH.GoetheJ.Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.Psychopharmacol Bull.1996326836978993092
   PubMedGoogle Scholar
• PrienRF.ColeJO.High-dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - Psychopharmacology Research Branch Collaborative Study Group.Arch Gen Psychiatry.1968184824954868797
   PubMed Web of Science ®Google Scholar
• DavisJM.CasperR.Antipsychotic drugs: clinical pharmacology and therapeutic use.Drugs.19771426028221069
   PubMed Web of Science ®Google Scholar
• EssockSM.HargreavesWA.DohmFA.GoetheJ.CarverL.HipshmanL.Clozapine eligibility among state hospital patients.Schizophr Bull.19962215258685657
   PubMed Web of Science ®Google Scholar
• McGlashanTH.A selective review of recent North American long-term followup studies of schizophrenia.Schizophr Bull.1988145155423064280
   PubMed Web of Science ®Google Scholar
• RevickiDA.LuceBR.WeschlerJM.BrownRE.AdlerMA.Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.Hosp Commun Psychiatry.199041850854
   PubMedGoogle Scholar
• MeltzerHY.OkayliG.Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.Am J Psychiatry.19951521831907840350
   PubMed Web of Science ®Google Scholar
• OplerLA.CatonCL.ShroutP.DominguezB.KassFl.Symptom profiles and homelessness in schizophrenia.J Nerv Ment Dis.19941821741787906710
   PubMed Web of Science ®Google Scholar
• SheitmanBB.LiebermanJA.The natural history and pathophysiology of treatment-resistant schizophrenia.J Psychiatr Res.1998321431509793867
   PubMed Web of Science ®Google Scholar
• KaneJ.HonigfeldG.SingerJ.MeltzerH.Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine.Arch Gen Psychiatry.1988457897963046553
   PubMed Web of Science ®Google Scholar
• KaneJM.MarderSR.Psychopharmacologic treatment of schizophrenia.Schizophr Bull.1993192873028100642
   PubMed Web of Science ®Google Scholar
• BarnesTR.McEvedyCJ.Pharmacological treatment strategies in the non-responsive schizophrenic patient.Int Clin Psychopharmacol.199611(suppl2)67718803663
   PubMed Web of Science ®Google Scholar
• DixonLB.LehmanAF.LevineJ.Conventional antipsychotic medications for schizophrenia.Schizophr Bull.1995215675778749885
   PubMed Web of Science ®Google Scholar
• KinonBJ.KaneJM.JohnsC.et al.Treatment of neuroleptic-resistant schizophrenic relapse.Psychopharmacol Bull.1993293093147904762
   PubMedGoogle Scholar
• KinonBJ.KaneJM.ChakosM.MunneR.Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.Psychopharmacol Bull.1993293653697907184
   PubMedGoogle Scholar
• TammingaCA.BuchananRW.GoldJM.The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.Int Clin Psychopharmacol.199813(suppl 3)S21S269690966
   PubMed Web of Science ®Google Scholar
• AndreasenNC.Improvement of negative symptoms. Concepts, definition and assessment.Int Clin Psychopharmacol.199712(suppl 2)S7S109218162
   PubMed Web of Science ®Google Scholar
• DavidsonM.KeefeRS.Cognitive impairment as a target for pharmacological treatment in schizophrenia.Schizophr Res.1995171231298541245
   PubMed Web of Science ®Google Scholar
• GoldbergTE.WeinbergerDR.Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.J Clin Psychiatry.199657(suppl 9)62658823353
   PubMed Web of Science ®Google Scholar
• PurdonSE.JonesBD.StipE.et al.Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for Research in Schizophrenia.Arch Gen Psychiatry.20005724925810711911
   PubMed Web of Science ®Google Scholar
• GreenMF.MarderSR.GlynnSM.et al.The neurocognitive effects of low-dose haloperidol: a 2-year comparison with risperidone.Biol Psychiatry.20025197297812062881
   PubMed Web of Science ®Google Scholar
• KeefeRS.SilvaSG.PerkinsDO.LiebermanJA.The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.Schizophr Bull.19992520122210416727
   PubMed Web of Science ®Google Scholar
• KatschnigH.Schizophrenia and quality of life.Acta Psychiatr Scand Suppl.2000102333711261637
   PubMedGoogle Scholar
• AwadAG.VorugantiLN.Intervention research in psychosis: issues related to the assessment of quality of life.Schizophr Bull.20002655756410993397
   PubMed Web of Science ®Google Scholar
• DickersonF.BoronowJJ.RingelN.ParenteF.Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year followup.Schizophr Res.199937132010227104
   PubMed Web of Science ®Google Scholar
• AddingtonJ.AddingtonD.Neurocognitive and social functioning in schizophrenia: a 2.5-year follow-up study.Schizophr Res.200044475610867311
   PubMed Web of Science ®Google Scholar
• AtkinsonJM.CoiaDA.GilmourWH.HarperJP.The impact of education groups for people with schizophrenia on social functioning and quality of life.Br J Psychiatry.19961681992048837910
   PubMed Web of Science ®Google Scholar
• LindenmayerJP.Treatment refractory schizophrenia.Psychiatr Q.20007137338411025914
   PubMed Web of Science ®Google Scholar
• BrennerHD.DenckerSJ.GoldsteinMJ.et al.Defining treatment refractoriness in schizophrenia.Schizophr Bull.1990165515611981813
   PubMed Web of Science ®Google Scholar
• RobinsonDG.WoernerMG.AlvirJM.et al.Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.Am J Psychiatry.199915654454910200732
   PubMed Web of Science ®Google Scholar
• SzymanskiS.LiebermanJA.AlvirJM.et al.Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.Am J Psychiatry.19951526987037726309
   PubMed Web of Science ®Google Scholar
• MeltzerHY.RabinowitzJ.LeeMA.et al.Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.Am J Psychiatry.19971544754829090333
   PubMed Web of Science ®Google Scholar
• LiebermanJA.SaffermanAZ.PollackS.et al.Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.Am J Psychiatry.1994151174417527977880
   PubMed Web of Science ®Google Scholar
• LiebermanJA.KaneJM.SaffermanAZ.et al.Predictors of response to clozapine.J Clin Psychiatry.199455(suppl B)1261287961556
   PubMed Web of Science ®Google Scholar
• MalaspinaD.GoetzRR.YaleS.et al.Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome.Am J Psychiatry.2000157994100310831482
   PubMed Web of Science ®Google Scholar
• BartkoG.FrecskaE.HorvathS.ZadorG.AratoM.Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients.Acta Psychiatr Scand.1990824084121981296
   PubMed Web of Science ®Google Scholar
• AlvirJM.WoernerMG.GunduzH.DegreefG.LiebermanJA.Obstetric complications predict treatment response in first-episode schizophrenia.Psychol Med.19992962162710405083
   PubMed Web of Science ®Google Scholar
• LiebermanJA.AlvirJM.KoreenA.et al.Psychobiologic correlates of treatment response in schizophrenia.Neuropsychopharmacology.19961413S21S8866739
   PubMed Web of Science ®Google Scholar
• WieselgrenIM.LindstromLH.A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment.Acta Psychiatr Scand.1996939198919324
   PubMed Web of Science ®Google Scholar
• BailerJ.BrauerW.ReyER.Premorbid adjustment as predictor of outcome in schizophrenia: results of a prospective study.Acta Psychiatr Scand.1996933683778792907
   PubMed Web of Science ®Google Scholar
• LiebermanJA.AlvirJM.WoernerM.et al.Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital.Schizophr Bull.1992183513711411327
   PubMed Web of Science ®Google Scholar
• EdwardsJ.MaudeD.McGorryPD.HarriganSM.CocksJT.Prolonged recovery in first-episode psychosis.Br J Psychiatry Suppl.19981721071169764136
   PubMedGoogle Scholar
• KinonBJ.KaneJM.ChakosM.MunneR.Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.Psychopharmacol Bull.1993293653697907184
   PubMedGoogle Scholar
• KolakowskaT.WilliamsAO.JamborK.ArdernM.Schizophrenia with good and poor outcome. III. Neurological “soft” signs, cognitive impairment and their clinical significance.Br J Psychiatry.19851463483574016437
   PubMed Web of Science ®Google Scholar
• SchulzSC.ConleyRR.KahnEM.et al.Nonresponders to neuroleptics: a distinct subtype. In: Tamminga CA, ed.Schizoprenia Scientific Progress. Oxford, UK: Oxford University Press1989341350
   Google Scholar
• WiersmaD.WanderlingJ.DragomireckaE.et al.Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres.Psychol Med.2000301155116712027051
   PubMed Web of Science ®Google Scholar
• BilderRM.WuH.ChakosMH.et al.Cerebral morphometry and clozapine treatment in schizophrenia.J Clin Psychiatry.199455(suppl B)53567961574
   PubMed Web of Science ®Google Scholar
• SternRG.KahnRS.DavidsonM.Predictors of response to neuroleptic treatment in schizophrenia.Psychiatr Clin North Am.1993163133388101371
   PubMed Web of Science ®Google Scholar
• OtaT.MaeshiroH.IshidoH.et al.Treatment-resistant chronic psychopathology and CT scans in schizophrenia.Acta Psychiatr Scand.1987754154273591423
   PubMed Web of Science ®Google Scholar
• WeinbergerDR.BigelowLB.KleinmanJE.KleinST.RosenblattJE.WyattRJ.Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment.Arch Gen Psychiatry.19803711136101534
   PubMed Web of Science ®Google Scholar
• KaplanMJ.LazoffM.KellyK.LukinR.GarverDL.Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics.Biol Psychiatry.1990272052142294982
   PubMed Web of Science ®Google Scholar
• KirkpatrickB.ConleyRC.KakoyannisA.ReepRL.RobertsRC.Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: an unbiased cell-counting study.Synapse.1999349510210502308
   PubMed Web of Science ®Google Scholar
• DegreefG.BogertsB.FalkaiP.et al.Increased prevalence of the cavum septum pellucidum in magnetic resonance scans and post-mortem brains of schizophrenic patients.Psychiatry Res.1992451131410074
   PubMed Web of Science ®Google Scholar
• van KarnmenDP.SchoolerN.Are biochemical markers for treatment-resistant schizophrenia state dependent or traits?Clin Neuropharmacol.199013(suppl 1)S16S282199034
   PubMed Web of Science ®Google Scholar
• van KammenDP.BunneyWE.Jr.DochertyJP.et al. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.Am J Psychiatry.19821399919977091448
   PubMed Web of Science ®Google Scholar
• LiebermanJA.Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia.J Clin Psychiatry.199960(suppl 12)91210372603
   PubMed Web of Science ®Google Scholar
• CahnW.PolHE.LemsEB.et al.Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.Arch Gen Psychiatry.2002591002101012418933
   PubMed Web of Science ®Google Scholar
• FentonWS.BlylerCR.HeinssenRK.Determinants of medication compliance in schizophrenia: empirical and clinical findings.Schizophr Bull.1997236376519366000
   PubMed Web of Science ®Google Scholar
• MarderSR.Antipsychotic drugs and relapse prevention.Schizophr Res.199935(suppl)S87S9210190229
   PubMed Web of Science ®Google Scholar
• FleischhackerWW.MeiseU.GuntherV.KurzM.Compliance with antipsychotic drug treatment: influence of side effects.Acta Psychiatr Scand Suppl.199438211157916523
   PubMedGoogle Scholar
• PekkalaE.MerinderL..Psychoeducation for schizophrenia.Cochrane Database Syst Rev.20022
   Google Scholar
• LeniorME. DP.ScheneAH.HartAA.LinszenDH.The course of parental expressed emotion and psychotic episodes after family intervention in recent-onset schizophrenia. A longitudinal study.Schizophr Res.20025718319012223249
   PubMed Web of Science ®Google Scholar
• PillingS. BP.KuipersE.GaretyP.GeddesJ.OrbachG.MorganC.Psychological treatments in schizophrenia. II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation.Psychol Med.20023278379112171373
   PubMed Web of Science ®Google Scholar
• Pitschel-WalzG.LeuchtS.BaumlJ.KisslingW.EngelRR.The effect of family interventions on relapse and rehospitalization in schizophrenia - a meta-analysis.Schizophr Bull.200127739211215551
   PubMed Web of Science ®Google Scholar
• ConleyRR.KellyDL.Management of treatment resistance in schizophrenia.Biol Psychiatry.20015089891111743944
   PubMed Web of Science ®Google Scholar
• HellewellJS.Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.J Clin Psychiatry.199960(suppl 23)141910625195
   PubMed Web of Science ®Google Scholar
• SternGR.SchmeidlerJ.DavidsonM.Limitations of controlled augmentation trials in schizophrenia.Biol Psychiatry.1997421381439209731
   PubMed Web of Science ®Google Scholar
• ChristisonGW.KirchDG.WyattRJ.When symptoms persist: choosing among alternative somatic treatments for schizophrenia.Schizophr Bull.1991172172451679252
   PubMed Web of Science ®Google Scholar
• BreierA.BuchananRW.IrishD.CarpenterWT. Jr.Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns.Hosp Commun Psychiatry.19934411451149
   PubMedGoogle Scholar
• MallyaAR.RoosPD.Roebuck-ColganK.Restraint, seclusion, and clozapine.J Clin Psychiatry.1992533953971459970
   PubMed Web of Science ®Google Scholar
• WilsonWH.Clinical review of clozapine treatment in a state hospital.Hosp Commun Psychiatry.199243700703
   PubMedGoogle Scholar
• MeltzerHY.AlphsL.GreenAI.et al.Clozapine treatment for suicidally in schizophrenia: International Suicide Prevention Trial (InterSePT).Arch Gen Psychiatry.200360829112511175
   PubMed Web of Science ®Google Scholar
• MoncrieffJ.Clozapine versus conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination.Br J Psychiatry.200318316116612893670
   PubMed Web of Science ®Google Scholar
• AvnonM.RabinowitzJ.Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia.Br J Psychiatry.19951677607648829743
   PubMed Web of Science ®Google Scholar
• ConleyRR.CarpenterWT. Jr.TammingaCA.Time to clozapine response in a standardized trial.Am J Psychiatry.1997154124312479286183
   PubMed Web of Science ®Google Scholar
• RosenheckR.EvansD.HerzL.et al.How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia.Schizophr Bull.19992570971910667741
   PubMed Web of Science ®Google Scholar
• CarpenterWT. Jr.ConleyRR.BuchananRW.BreierA.TammingaCA.Patient response and resource management: another view of clozapine treatment of schizophrenia.Am J Psychiatry.19951528278327755110
   PubMed Web of Science ®Google Scholar
• KronigMH.MunneRA.SzymanskiS.et al.Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.Am J Psychiatry.19951521791827840349
   PubMed Web of Science ®Google Scholar
• ChouinardG.VainerJL.BelangerMC.et al.Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.Prog Neuropsychopharmacol Biol Psychiatry.199418112911417531355
   PubMed Web of Science ®Google Scholar
• KeckPE. Jr.WilsonDR.StrakowskiSM.et al.Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.J Clin Psychiatry.1995564664707559373
   PubMed Web of Science ®Google Scholar
• WirshingDA.MarshallBD. Jr.GreenMF.MintzJ.MarderSR.WirshingWC.Risperidone in treatment-refractory schizophrenia.Am J Psychiatry.19991561374137910484947
   PubMed Web of Science ®Google Scholar
• ThomasSG.LabbateLA.Management of treatment-resistant schizophrenia with olanzapine.Can J Psychiatry.1998431951969533977
   PubMed Web of Science ®Google Scholar
• TollefsonGD.KuntzAJ.Review of recent clinical studies with olanzapine.Br J Psychiatry Suppl.1999303510211139
   PubMedGoogle Scholar
• MartinJ.GomezJC.Garcia-BernardoE.CuestaM.AlvarezE.GurpeguiM.Olanzapine in treatment-refractory schizophrenia: results of an openlabel study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.J Clin Psychiatry.1997584794839413413
   PubMed Web of Science ®Google Scholar
• DossenbachMRK.BeuzenJN.AvnonM.et al.The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.Clin Ther.2000221021103411048902
   PubMed Web of Science ®Google Scholar
• BreierA.HamiltonSH.Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.Biol Psychiatry.19994540341110071708
   PubMed Web of Science ®Google Scholar
• EmsleyRA.RaniwallaJ.BaileyPJ.JonesAM.A comparison of the effects of quetiapine (“seroquel”) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group.Int Clin Psychopharmacol.20001512113110870870
   PubMed Web of Science ®Google Scholar
• WeidenPJ.SimpsonGM.PotkinSG.O'SullivanRL.Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.J Clin Psychiatry.20036458058812755663
   PubMed Web of Science ®Google Scholar
• LindenmayerJP.CzoborP.VolavkaJ.et al.Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.J Clin Psychiatry.20026393193512416603
   PubMed Web of Science ®Google Scholar
• BondolfiG.DufourH.PatrisM.et al.Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.Am J Psychiatry.19981554995049545995
   PubMed Web of Science ®Google Scholar
• KlieserE.LehmannE.KinzlerE.WurthmannC.HeinrichK.Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia.J Clin Psychopharmacol.19951545S51S7537287
   PubMed Web of Science ®Google Scholar
• WahlbeckK.CheineM.TuiskuK.AhokasA.JoffeG.RimonR.Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.Prog Neuropsychopharmacol Biol Psychiatry.20002491192211041534
   PubMed Web of Science ®Google Scholar
• MeltzerHY.McGurkSR.The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophr Bull.19992523325510416729
   PubMed Web of Science ®Google Scholar
• HarveyPD.GreenMF.McGurkSR.MeltzerHY.Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.Psychopharmacology (Berl).200316940441112590356
   PubMed Web of Science ®Google Scholar
• BilderRM.GoldmanRS.VolavkaJ.et al.Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.Am J Psychiatry.20021591018102812042192
   PubMed Web of Science ®Google Scholar
• HarveyPD.MoriartyPJ.SerperMR.SchnurE.LieberD.Practice-related improvement in information processing with novel antipsychotic treatment.Schizophr Res.20004613914811120426
   PubMed Web of Science ®Google Scholar
• VorugantiL.CorteseL.OwyeumiL.et al.Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.Schizophr Res.20025720120812223251
   PubMed Web of Science ®Google Scholar
• HirschSR.KisslingW.BaumlJ.PowerA.O'ConnorR.A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.J Clin Psychiatry.20026351652312088164
   PubMed Web of Science ®Google Scholar
• SharmaT.Quetiapine - efficacy in different domains.Eur Neuropsychopharmacol.200111(suppl 4)S385S39011587885
   PubMed Web of Science ®Google Scholar
• SangerTM.LiebermanJA.TohenM.GrundyS.BeasleyC. Jr.TollefsonGD.Olanzapine versus haloperidol treatment in first-episode psychosis.Am J Psychiatry.199915679879892301
   PubMed Web of Science ®Google Scholar
• VolavkaJ.CzoborP.SheitmanB.et al.Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.Am J Psychiatry.200215925526211823268
   PubMed Web of Science ®Google Scholar
• BeasleyCM. Jr.TollefsonG.TranP.SatterleeW.SangerT.HamiltonS.Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.Neuropsychopharmacoiogy.199614111123
   PubMed Web of Science ®Google Scholar
• MarderSR.MeibachRC.Risperidone in the treatment of schizophrenia.Am J Psychiatry.19941518258357514366
   PubMed Web of Science ®Google Scholar
• BuchananRW.BreierA.KirkpatrickB.BallP.CarpenterWT. Jr.Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.Am J Psychiatry.19981557517609619146
   PubMed Web of Science ®Google Scholar
• MeltzerHY.An overview of the mechanism of action of clozapine.J Clin Psychiatry.199455(suppl B)47527961573
   PubMed Web of Science ®Google Scholar
• KeksNA.AltsonK.HopeJ.et al.Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service.Aust N Z J Psychiatry.19993389690110619218
   PubMed Web of Science ®Google Scholar
• AdesanyaA.PantelisC.Adjunctive risperidone treatment in patients with “clozapine-resistant schizophrenia.”Aust N Z J Psychiatry20003453353410881988
   PubMed Web of Science ®Google Scholar
• HendersonDC.GoffDC.Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.J Clin Psychiatry.1996573953979746446
   PubMed Web of Science ®Google Scholar
• RaskinS.KatzG.ZislinZ.KnoblerHY.DurstR.Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.Acta Psychiatr Scand.200010133433610782556
   PubMed Web of Science ®Google Scholar
• McCarthyRH.TerkelsenKG.Risperidone augmentation of clozapine.Pharmacopsychiatry.19952861637542786
   PubMed Web of Science ®Google Scholar
• TaylorCG.FlynnSW.AltmanS.EhmannT.MacEwanGW.HonerWG.An open trial of risperidone augmentation of partial response to clozapine.Schizophr Res.20014815515811345947
   PubMed Web of Science ®Google Scholar
• de GrootIW.HeckAH.van HartenPN.Addition of risperidone to clozapine therapy in chronically psychotic inpatients.J Clin Psychiatry.20016212913011247102
   PubMed Web of Science ®Google Scholar
• GuptaS.SonnenbergSJ.FrankB.Olanzapine augmentation of clozapine.Ann Clin Psychiatry.1998101131159781474
   PubMedGoogle Scholar
• LernerV.ChudakovaB.KravetsS.PolyakovaI.Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.Clin Neuropharmacol.20002328428611154098
   PubMed Web of Science ®Google Scholar
• MowermanS.SirisSG.Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients.Ann Clin Psychiatry.199681931978986313
   PubMedGoogle Scholar
• FriedmanJ.AultK.PowchikP.Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.Biol Psychiatry.1997425225239285089
   PubMed Web of Science ®Google Scholar
• ShilohR.ZemishlanyZ.AizenbergD.et al.Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.Br J Psychiatry.19971715695739519099
   PubMed Web of Science ®Google Scholar
• ArangoC. KB.BuchananRW.Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.J Nerv Ment Dis.2000188505310665462
   PubMed Web of Science ®Google Scholar
• SilverH.Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.Int Clin Psychopharmacol.20031830531314571150
   PubMed Web of Science ®Google Scholar
• SilverH.KushnirM.KaplanA.Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study.Biol Psychiatry.1996406716748886304
   PubMed Web of Science ®Google Scholar
• Jockers-ScherublM.GodemannF.PietzckerA.Negative symptoms of schizophrenia are improved by paroxetine added to neuroleptics: a pilot study.J Clin Psychiatry.20016257311488373
   PubMed Web of Science ®Google Scholar
• ThakoreJH.BertiC.DinanTG.An open trial of adjunctive sertraline in the treatment of chronic schizophrenia.Acta Psychiatr Scand.1996941941978891087
   PubMed Web of Science ®Google Scholar
• BuchananRW.KirkpatrickB.BryantN.BallP.BreierA.Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.Am J Psychiatry.1996153162516278942462
   PubMed Web of Science ®Google Scholar
• WhiteheadC.MossS.CardnoA.LewisG.Antidepressants for the treatment of depression in people with schizophrenia: a systematic review.Psychol Med.20033358959912785461
   PubMed Web of Science ®Google Scholar
• WhiteheadC.MossS.CardnoA.LewisG.Antidepressants for people with both schizophrenia and depression.Cochrane Database Syst Rev.2002CD00230512076447
   PubMedGoogle Scholar
• KaneJM.Schizophrenia.N Engl J Med.199633434417494570
   PubMed Web of Science ®Google Scholar
• CarmanJS.BigelowLB.WyattRJ.Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients.J Clin Psychiatry.1981421241286110654
   PubMed Web of Science ®Google Scholar
• GroweGA.CraytonJW.KlassDB.EvansH.StrizichM.Lithium in chronic schizophrenia.Am J Psychiatry.197913645445534327
   PubMed Web of Science ®Google Scholar
• SmallJG.KellamsJJ.MilsteinV.MooreJ.A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients.Am J Psychiatry.1975132131513171106217
   PubMed Web of Science ®Google Scholar
• WassefAA.DottSG.HarrisA.et al.Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia.J Clin Psychopharmacol.20002035736110831024
   PubMed Web of Science ®Google Scholar
• DoseM.HellwegR.YassouridisA.TheisonM.EmrichHM.Combined treatment of schizophrenic psychoses with haloperidol and valproate.Pharmacopsychiatry.1998311221259754845
   PubMed Web of Science ®Google Scholar
• SchulzSC.KahnEM.BakerRW.ConleyRR.Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In: Schulz SC, ed.The Neuroleptic-Nonresponsive Patient: Characterization and Treatment. Washington, DC: American Psychiatric Press;1990109136
   Google Scholar
• SimhandlC.MeszarosK.The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.J Psychiatry Neurosci.1992171141349823
   PubMed Web of Science ®Google Scholar
• HosakL.LibigerJ.Antiepileptic drugs in schizophrenia: a review.Eur Psychiatry.20021737137812547302
   PubMed Web of Science ®Google Scholar
• FriedelROThe combined use of neuroleptics and ECT in drug-resistant schizophrenic patients.Psychopharmacol Bull.1986229289303797594
   PubMedGoogle Scholar
• KupchikM.SpivakB.MesterR.et al.Combined electroconvulsive-clozapine therapy.Clin Neuropharmacol.200023141610682225
   PubMed Web of Science ®Google Scholar
• KalesHC.DequardoJR.TandonR.Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry.19992354755610378236
   PubMed Web of Science ®Google Scholar
• BhatiaSC.BhatiaSK.GuptaS.Concurrent administration of clozapine and ECT: a successful therapeutic strategy for a patient with treatment-resistant schizophrenia.J ECT.1998142802839871852
   PubMed Web of Science ®Google Scholar
• BenatovR.SirotaP.MeggedS.Neuroleptic-resistant schizophrenia treated with clozapine and ECT.Convuls Ther.1996121171218744173
   PubMedGoogle Scholar
• RemingtonGJ.AddingtonD.CollinsEJ.et al.Clozapine: current status and role in the pharmacotherapy of schizophrenia.Can J Psychiatry.1996411611668722645
   PubMedGoogle Scholar
• ChanpattanaW.KramerBA.Acute and maintenance ECT with flu penthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes.Schizophr Res.20036318919312892873
   PubMed Web of Science ®Google Scholar
• ChanpattanaW.ChakrabhandML.Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome.Psychiatry Res.200110510711511740980
   PubMed Web of Science ®Google Scholar